AOD-9604 vs Full-Length Growth Hormone: What the Research Compares

AOD-9604 is derived from human growth hormone (hGH), which raises an obvious research question: how does the fragment's studied profile compare to the full molecule it comes from? Here's what the published literature actually compares — again, framed as laboratory and animal-model findings rather than claims about human use.

Same lipolytic region, much smaller molecule

Full-length hGH is a 191-amino-acid protein with wide-ranging, well-documented actions across growth, metabolism, and tissue signaling, mediated through the GH receptor [1, 2]. AOD-9604 corresponds to only a small C-terminal fragment of that sequence (the region spanning roughly amino acids 176–191), the part of the molecule researchers have associated specifically with hGH's studied lipolytic (fat-metabolizing) activity [1, 6]. Because it is a small fragment rather than the full protein, published research has investigated whether it retains that narrower, studied activity while diverging from hGH elsewhere.

Where the animal-model research diverges

The foundational comparison comes from a study in obese Zucker rats: both AOD-9604 and full-length hGH were evaluated for their effect on body-weight gain and insulin sensitivity (measured by euglycemic clamp). Full-length hGH's association with reduced insulin sensitivity is well established in the broader hGH literature; the researchers reported that AOD-9604, by contrast, showed no measured negative effect on insulin sensitivity in that same study design [1]. A separate line of research in obese and beta-3-adrenergic-receptor knockout mice found that both hGH and AOD-9604 elevated β3-AR expression and reduced body weight over a 14-day treatment period in normal obese mice, but that receptor-independent effects were also observed for AOD-9604 specifically [2].

Human safety data: a difference in what was studied

Full-length hGH carries a long, well-characterized human safety and pharmacology record tied to its approved medical uses. AOD-9604's human data comes from a different context: a pooled analysis of six early-phase trials (approximately 893 healthy, obese adults) designed specifically to evaluate the fragment's safety and tolerability — not a therapeutic outcome. That analysis reported a safety profile "indistinguishable from placebo" and no clinically significant change in IGF-1, a growth-hormone-pathway marker that full-length hGH is well known to elevate [3].

The honest limitation

Despite the favorable safety and mechanism-level research, a later phase IIB clinical trial evaluating AOD-9604 specifically as an obesity treatment did not produce results supporting commercial development for that indication, according to an independent peer-reviewed review of obesity pharmacotherapies [6]. That result is part of the research record and belongs in any accurate comparison — mechanism-level and animal-model findings are not the same as a validated therapeutic outcome in people.